Top Tweets for #BioSimilars
🇧🇷 Two incredible days at #BiosimilarsLatAm2026!
Thank you to our Sponsors, Speakers, Panelists, Strategic Partners, Media Partner & every Attendee for the insights, connections and conversations.
One shared mission:
🌎 Advancing access to #biosimilars across Latin America.
Arzneimittelausgaben in #Italien: 39,3 Mrd. € (2025). Der #OsMed-Bericht zeigt steigende Ausgaben, Therapien & #Biosimilars.
https://t.co/9tDoWhzvAU
#Gesundheit #AIFA
Lupin bets Biosimilars to cross $100 Mn scale in 3 years; plans in-licensing to innovate India biz
#Pharma I #Biosimilars I #Revenue I #Q1_earnings I #FY27 I #Innovation I #In_licensing I @LupinGlobal
Read more:
https://t.co/AsWMRYqZU4
Biosimilars are transforming access and care. This month’s CFB newsletter highlights key FDA actions, policy shifts, and research on switching and long-term safety. Discover the latest insights here: https://t.co/YqqZR50EdI
#Biosimilars #HealthPolicy
Biocon Q1 FY27 Concall: Biosimilars Lead Growth as Management Raises Long Term Confidence #biocon #q1fy27 #concall #results #biosimilars #pharma #generics #glp1 #biologics #fda #managementcommentary #stockmarketindia
https://t.co/DLu4RXHOvR
Biocon Q1 FY27 Concall: Biosimilars Lead Growth as Management Raises Long Term Confidence #biocon #q1fy27 #concall #results #biosimilars #pharma #generics #glp1 #biologics #fda #managementcommentary #stockmarketindia
https://t.co/U931QDN7Mj
#Biologics, #GLP1s driving evolution of #fillfinish manufacturing. Manufacturers are expanding capacity while adopting #automation, #isolatortechnology, and new #workforce strategies to meet increasing demands. https://t.co/ScIqBMaFQt #CDMOs #CDMO #sterileinjectables #biosimilars
Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix.
https://t.co/nGd2z4vlk8
#Biocon #Q1Results #Biosimilars | @AnjaliS92652729
Business Intelligence | Biocon Q1 FY27 Revenue Rises 10% to Rs 4,336 Crore as Biopharma Business Leads Growth.
Full data analysis on BiotechReality:
https://t.co/Ag7zjaPlIq
#Biocon #Q1FY27 #QuarterlyResults #Biosimilars #Generics #BioconBiologics #KiranMazumdarShaw #Denosumab
Biocon Posts 9% Rise In Q1 Total Income; Biopharma Revenue Up 17%
#Biocon #Biosimilars #PharmaNews #GLP1 #BusinessToday
@neetu_csharma | @Bioconlimited
Biocon Q1 FY27 revenue rises 10% to Rs 4,336 crore on strong biosimilars performance
https://t.co/q7Cvmh54Ea
#Biocon #Syngene #biosimilars #biopharmaceuticals #KiranMazumdar-Shaw #Aukelso #EuropeanMedicinesAgency #Liraglutide #Bosaya
@indpharmapost
US device user fees take a hike, drug fees relatively stable https://t.co/uQUFffYGe3 #biopharma #medtech @US_FDA #biosimilars #BsUFA #generics #GDUFA #MDUFA #PDUFA
LAST CALL, #BiosimilarsLatAm – #Brazil2026 !
This is your final chance to register & join the most influential #biosimilars leaders in Latin America.
https://t.co/HPuJos2hCl
Regulators, decision-makers and top pharma executives will define the future of biosimilars in the region.
Business Intelligence | Sun Pharma Q1FY27 Results: Sales Rise 10.1% to Rs1,518 Mn
Full data analysis on BiotechReality:
https://t.co/ejThL2oO1K
#SunPharma #Q1FY27 #QuarterlyResults #IndiaFormulations #GlobalInnovativeMedicines #Organon #Biosimilars #WomensHealth #Semaglutide
A decade-old rulebook for biosimilars is being rewritten. EMA wants less clinical redundancy, more scientific precision — reshaping how biosimilarity gets proven, and how its dossiers get written, from here on.
https://t.co/hBsIRG63pI
#RegulatoryMedicalWriting #Biosimilars #EMA
Biocon strengthens eye care portfolio with Yesafili US rollout
For more details : https://t.co/154iLuYoMR
#Biocon #Biosimilars #HealthcareInnovation n
#India is showing how #biosimilars can transform #healthcare by making sight-saving anti-VEGF therapies more affordable and accessible without compromising on safety or efficacy. As the first country to commercialise a ranibizumab biosimilar, India continues to demonstrate that innovation and affordability can go hand in hand. A powerful example of healthcare equity in action.
https://t.co/KEmcqLHwYr
Biologics = 5% of scripts…
…but >50% of drug spend 💰
Biosimilars could reshape oncology costs in the years ahead.
🔗 Learn more: https://t.co/X4blMH5pt1 #biosimilars #pharmacy
Trump's announcement on #generics tariffs of 100% should prompt a broader discussion: Manufacturing investment is important, but so are policies that enable #biosimilars competition. Together they can improve affordability, strengthen supply chains and expand patient access.
The US president said some of the most widely used drugs in the country would face tariffs of 100% from August 2028, rising to 200% a year later as part of his latest effort to move manufacturing to America. https://t.co/ecX5g0krLk
Biologics = 5% of scripts…
…but >50% of drug spend 💰
Biosimilars could reshape oncology costs in the years ahead.
🔗 Learn more: https://t.co/X4blMH5pt1 #biosimilars #pharmacy
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
82.9M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers